Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
Kline, A. E.; Yu, J.; Horváth, E.; Marion, D. W.; Dixon, C. E. (2001). „The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats”. Neuroscience106 (3): 547–555. DOI:10.1016/S0306-4522(01)00300-1. PMID11591455.
Mauler, F.; Horváth, E. (2005). „Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury”. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism25 (4): 451–459. DOI:10.1038/sj.jcbfm.9600038. PMID15674237.
Ohman, J.; Braakman, R.; Legout, V.; Traumatic Brain Injury Study Group (2001). „Repinotan (BAY x 3702): a 5HT1A agonist in traumatically brain injured patients”. Journal of neurotrauma18 (12): 1313–1321. DOI:10.1089/08977150152725614. PMID11780862.
Lutsep, H. L. (2005). „Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke”. Current drug targets. CNS and neurological disorders4 (2): 119–120. DOI:10.2174/1568007053544165. PMID15857296.
Berends, A. C.; Luiten, P. G.; Nyakas, C. (2005). „A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke”. CNS Drug Reviews11 (4): 379–402. DOI:10.1111/j.1527-3458.2005.tb00055.x. PMID16614737.
Teal, P.; Davis, S.; Hacke, W.; Kaste, M.; Lyden, P.; Modified Randomized Exposure Controlled Trial Study Investigators; Fierus, M.; Bayer Healthcare, A. (2009). „A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)”. Stroke; a journal of cerebral circulation40 (11): 3518–3525. DOI:10.1161/STROKEAHA.109.551382. PMID19745176.
Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, Putensen C, Hoeft A (October 2010). „Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats”. Anesthesia and Analgesia111 (4): 901–7. DOI:10.1213/ANE.0b013e3181eac011. PMID20802053.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
De Vry, J.; Schohe-Loop, R.; Heine, H. G.; Greuel, J. M.; Mauler, F.; Schmidt, B.; Sommermeyer, H.; Glaser, T. (1998). „Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist”. The Journal of Pharmacology and Experimental Therapeutics284 (3): 1082–1094. PMID9495870.
Dong, J.; De Montigny, C.; Blier, P. (1998). „Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe”. The Journal of Pharmacology and Experimental Therapeutics286 (3): 1239–1247. PMID9732384.
Kline, A. E.; Yu, J.; Horváth, E.; Marion, D. W.; Dixon, C. E. (2001). „The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats”. Neuroscience106 (3): 547–555. DOI:10.1016/S0306-4522(01)00300-1. PMID11591455.
Mauler, F.; Horváth, E. (2005). „Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury”. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism25 (4): 451–459. DOI:10.1038/sj.jcbfm.9600038. PMID15674237.
Ohman, J.; Braakman, R.; Legout, V.; Traumatic Brain Injury Study Group (2001). „Repinotan (BAY x 3702): a 5HT1A agonist in traumatically brain injured patients”. Journal of neurotrauma18 (12): 1313–1321. DOI:10.1089/08977150152725614. PMID11780862.
Lutsep, H. L. (2005). „Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke”. Current drug targets. CNS and neurological disorders4 (2): 119–120. DOI:10.2174/1568007053544165. PMID15857296.
Berends, A. C.; Luiten, P. G.; Nyakas, C. (2005). „A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke”. CNS Drug Reviews11 (4): 379–402. DOI:10.1111/j.1527-3458.2005.tb00055.x. PMID16614737.
Teal, P.; Davis, S.; Hacke, W.; Kaste, M.; Lyden, P.; Modified Randomized Exposure Controlled Trial Study Investigators; Fierus, M.; Bayer Healthcare, A. (2009). „A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)”. Stroke; a journal of cerebral circulation40 (11): 3518–3525. DOI:10.1161/STROKEAHA.109.551382. PMID19745176.
Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, Putensen C, Hoeft A (October 2010). „Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats”. Anesthesia and Analgesia111 (4): 901–7. DOI:10.1213/ANE.0b013e3181eac011. PMID20802053.